Philogen S.p.A. (BIT:PHIL)
Italy flag Italy · Delayed Price · Currency is EUR
22.90
+0.40 (1.78%)
May 14, 2025, 5:35 PM CET
29.01%
Market Cap 906.52M
Revenue (ttm) 77.65M
Net Income (ttm) 45.29M
Shares Out 40.29M
EPS (ttm) n/a
PE Ratio 20.01
Forward PE 10.32
Dividend n/a
Ex-Dividend Date n/a
Volume 11,497
Average Volume 7,284
Open 22.50
Previous Close 22.50
Day's Range 22.50 - 22.90
52-Week Range 16.50 - 22.90
Beta 0.15
RSI 83.37
Earnings Date May 6, 2025

About Philogen

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 165
Stock Exchange Borsa Italiana
Ticker Symbol PHIL
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.